Use the Back button in your browser to see the other results of your search or to select another record.

Detailed Search Results

Exercise performance after salbutamol inhalation in non-asthmatic, non-athlete individuals: a randomised, controlled, cross-over trial [with consumer summary]
Eckerstrom F, Rex CE, Maagaard M, Rubak S, Hjortdal VE, Heiberg J
BMJ Open Sport & Exercise Medicine 2018;4(1):e000397
clinical trial
6/10 [Eligibility criteria: Yes; Random allocation: Yes; Concealed allocation: Yes; Baseline comparability: No; Blind subjects: Yes; Blind therapists: No; Blind assessors: No; Adequate follow-up: Yes; Intention-to-treat analysis: No; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*

BACKGROUND: Asthma is a frequent diagnosis in competitive sports, and inhaled beta2-agonists are commonly used by athletes. Although inhaled beta2-agonists do not seem to improve performance in athletes, it has remained uncertain whether they can increase exercise performance in non-athletes. OBJECTIVE: To investigate the effect of inhaled beta2-agonists on exercise performance in healthy non-athlete individuals. METHODS: In a double-blinded, placebo-controlled, cross-over trial, healthy, non-asthmatic, non-athlete individuals were randomised to inhalation of either 900 microg of salbutamol or placebo. Cardiopulmonary exercise testing, dynamic spirometry and impulse oscillometry were performed. The primary outcome was the effect from salbutamol on peak oxygen uptake, whereas secondary outcomes were breathing reserve and ventilation efficiency, and workload, heart rate, breath rate and minute ventilation at peak exercise under influence of salbutamol. RESULTS: A total of 36 healthy subjects with a mean age of 26 +/- 5 years were included. Salbutamol had no effect on peak oxygen uptake compared with placebo, 46.8 +/- 1.3 mL/kg/min versus 46.6 +/- 1.2 mL/kg/min, p = 0.64. Salbutamol had no effect on workload, p = 0.20, heart rate, p = 0.23, breath rate, p = 0.10, or minute ventilation, p = 0.26, at peak exercise compared with placebo. Salbutamol lowered oxygen uptake, p = 0.04, and workload, p = 0.04, at anaerobic threshold compared with placebo. Forced expiratory volume in 1 s, 116% +/- 13% of predicted, and peak expiratory flow, 122% +/- 16% of predicted, increased after inhalation of salbutamol compared with placebo; 109% +/- 13% and 117% +/- 17%, respectively, p < 0.01. Breathing reserve was found to be higher, 22% +/- 2%, after salbutamol inhalation than after placebo, 16% +/- 2%, p < 0.01. CONCLUSION: Inhaled salbutamol did not improve peak oxygen uptake in healthy, non-asthmatic, non-athlete individuals compared with placebo. TRIAL REGISTRATION NUMBER: NCT02914652.

Full text (sometimes free) may be available at these link(s):      help